Raymond James Financial’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$146K Buy
47,754
+18,570
+64% +$61.7K ﹤0.01% 5157
2026
Q2
$108K Buy
29,184
+17,140
+142% +$56.9K ﹤0.01% 5166
2026
Q1
$41.9K Sell
12,044
-15,000
-55% -$57.1K ﹤0.01% 5139
2025
Q4
$93.8K Sell
27,044
-4,763
-15% -$21.2K ﹤0.01% 4938
2025
Q3
$176K Buy
31,807
+30,243
+1,934% +$123K ﹤0.01% 4658
2025
Q2
$3.86K Buy
+1,564
New +$2.41K ﹤0.01% 6246

Other funds holding PRME

Raymond James Financial's PRME Position: Q3 2026 in Review

Raymond James Financial increased its Prime Medicine (PRME) stake by 64% in Q3 2026, buying an estimated $61.7K and bringing the position to 47,754 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #5157.

Raymond James Financial first reported a position in PRME in Q2 2025 and has held it in 6 quarters since. The position peaked at $176K in Q3 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Raymond James Financial held 47,754 shares of Prime Medicine worth $146K as of Q3 2026.
  • Raymond James Financial bought 18,570 Prime Medicine shares in Q3 2026, an estimated $61.7K.
  • Prime Medicine made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5157 holding.
  • Raymond James Financial first reported a position in Prime Medicine in Q2 2025 and has held it in 6 quarters since.
  • Raymond James Financial's Prime Medicine position peaked at $176K in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.